A Phase 1/2 interventional study of Relatlimab and Nivolumab in Carcinoma, Hepatocellular, sponsored by Bristol-Myers Squibb. Completed at 61 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb — 3 open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Hepatocellular · Bristol-Myers Squibb.
Among the 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb, this one is the 13th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 1/2, and was the 18th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →3 of the 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Australia, Chile and 11 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Japan
Ages 18+
RayzeBio, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 9 · Phase 3 5
First in 2006; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 198 across the 19 interventional studies, 813 across the 2 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ascites as defined by:
i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Relatlimab · Drug: Nivolumab · Drug: Bevacizumab
Drug: Nivolumab · Drug: Bevacizumab · Other: Placebo
Specified dose on specified days
Also known as: BMS-986016
Specified dose on specified days
Also known as: BMS-936558, Opdivo
Specified dose on specified days
Also known as: Avastin
Specified dose on specified days
Number of Participants With Dose Limiting Toxicities
Bevacizumab DLTs: Include any AE causing \>42-day delay, GI perforation, nephrotic syndrome, Grade 3/4 infusion reactions, Death events, neutropenic fever, most non-hematologic toxicities (with specified exceptions), prolonged severe GI/electrolyte issues, significant fatigue, severe liver enzyme elevation, PRES/RPLS, severe hypertension or cardiac events, thromboembolism, major bleeding, wound complications, fistula, necrotizing fasciitis, and severe hematologic toxicity. Immunotherapy DLTs: Include severe immune-related events (eg, colitis, pneumonitis, uveitis), Grade 4 organ toxicities, serious hypersensitivity, prolonged/recurrent AEs, severe electrolyte/GI/fatigue events, Grade 5 events, severe hematologic, hepatic, neurologic, cardiac (myocarditis), and severe dermatologic reactions (eg, SJS/TEN, DRESS).
Time frame: From Day 1 (first dose) untill 6 weeks post first dose
Objective Response Rate (ORR) Assessed by BICR - All Comer Population
Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Objective Response Rate (ORR) Assessed by BICR - All EHSS No Population
Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Progression-Free Survival (All Comer Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)
Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). Disease progression is defined as Unequivocal progression of existing non-target lesions.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Progression-Free Survival (All EHSS No Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)
Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). Disease progression is defined as unequivocal progression of existing non-target lesions.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Objective Response Rate (ORR) Per BICR - All Comer Population in Participants With LAG-3 Positive Status(≥1% by IHC)
Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Objective Response Rate (ORR) Per BICR - All EHSS No Population in Participants With LAG-3 Positive Status(≥1% by IHC)
Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Number of Participants With Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)
Number of Participants With Select Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)
Number of Participants With Immune Mediated Endocrine Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)
| Milestone | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| Started | 42 | 40 |
| Completed | 6 | 7 |
| Not completed | 36 | 33 |
| Withdrew: Other reasons | 4 | 5 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Participant request to discontinue study | 4 | 1 |
| Withdrew: Death | 4 | 3 |
| Withdrew: Physician decision | 3 | 7 |
| Withdrew: Lack of efficacy | 20 | 15 |
Bevacizumab DLTs: Include any AE causing \>42-day delay, GI perforation, nephrotic syndrome, Grade 3/4 infusion reactions, Death events, neutropenic fever, most non-hematologic toxicities (with specified exceptions), prolonged severe GI/electrolyte issues, significant fatigue, severe liver enzyme elevation, PRES/RPLS, severe hypertension or cardiac events, thromboembolism, major bleeding, wound complications, fistula, necrotizing fasciitis, and severe hematologic toxicity. Immunotherapy DLTs: Include severe immune-related events (eg, colitis, pneumonitis, uveitis), Grade 4 organ toxicities, serious hypersensitivity, prolonged/recurrent AEs, severe electrolyte/GI/fatigue events, Grade 5 events, severe hematologic, hepatic, neurologic, cardiac (myocarditis), and severe dermatologic reactions (eg, SJS/TEN, DRESS).
| Participants | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| Number of Participants With Dose Limiting Toxicities | 0 | 1 |
Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| Objective Response Rate (ORR) Assessed by BICR - All Comer Population | 31.0 (19.4 to 44.6) | 37.5 (24.7 to 51.7) |
Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| Objective Response Rate (ORR) Assessed by BICR - All EHSS No Population | 31.8 (16.0 to 51.5) | 44.4 (24.4 to 65.9) |
Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). Disease progression is defined as Unequivocal progression of existing non-target lesions.
| months | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| Progression-Free Survival (All Comer Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC) | 13.44 (6.77 to 19.38) | 12.62 (1.45 to NA) |
Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). Disease progression is defined as unequivocal progression of existing non-target lesions.
| months | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| Progression-Free Survival (All EHSS No Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC) | 14.92 (5.62 to NA) | 7.03 (1.41 to NA) |
Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| Objective Response Rate (ORR) Per BICR - All Comer Population in Participants With LAG-3 Positive Status(≥1% by IHC) | 53.8 (28.7 to 77.6) | 53.3 (30.0 to 75.6) |
Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| Objective Response Rate (ORR) Per BICR - All EHSS No Population in Participants With LAG-3 Positive Status(≥1% by IHC) | 40.0 (7.6 to 81.1) | 50.0 (19.3 to 80.7) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| Adverse Events | 42 | 40 |
| Serious Adverse Events | 20 | 23 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| Gastrointestinal adverse event | 11 | 9 |
| Hepatic adverse event | 9 | 9 |
| Pulmonary adverse event | 2 | 1 |
| Renal adverse event | 6 | 4 |
| Skin adverse event | 18 | 10 |
| Hypersensitivity/infusion reaction | 1 | 2 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| Adrenal insufficiency | 3 | 3 |
| Hypothyroidism | 8 | 0 |
| Hyperthyroidism | 1 | 1 |
Collected over All cause mortality was collected up to approximately 42 months. AEs and SAEs were collected from first dose (Day 1) till Day 135 after last dose (up to approximately 38 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Relatlimab + Nivolumab + Bevacizumab | 29/42 (69%) | 25/42 (59.5%) | 42/42 (100%) |
| Placebo + Nivolumab + Bevacizumab | 18/40 (45%) | 26/40 (65%) | 38/40 (95%) |
| Event | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 7/42 | 2/40 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 3/42 | 2/40 |
| General physical health deteriorationGeneral disorders | 3/42 | 0/40 |
| AscitesGastrointestinal disorders | 2/42 | 2/40 |
| HaematemesisGastrointestinal disorders | 0/42 | 2/40 |
| Varices oesophagealGastrointestinal disorders | 0/42 | 2/40 |
| SepsisInfections and infestations | 0/42 | 2/40 |
| Hepatic encephalopathyNervous system disorders | 1/42 | 2/40 |
| PyrexiaGeneral disorders | 2/42 | 1/40 |
| AnaemiaBlood and lymphatic system disorders | 1/42 | 1/40 |
| Event | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab |
|---|---|---|
| HypertensionVascular disorders | 15/42 | 11/40 |
| DiarrhoeaGastrointestinal disorders | 11/42 | 9/40 |
| ProteinuriaRenal and urinary disorders | 10/42 | 10/40 |
| PruritusSkin and subcutaneous tissue disorders | 10/42 | 4/40 |
| PyrexiaGeneral disorders | 9/42 | 3/40 |
| Decreased appetiteMetabolism and nutrition disorders | 9/42 | 6/40 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/42 | 8/40 |
| ThrombocytopeniaBlood and lymphatic system disorders | 8/42 | 3/40 |
| HypothyroidismEndocrine disorders | 8/42 | 2/40 |
| RashSkin and subcutaneous tissue disorders | 8/42 | 5/40 |
| Age, Continuous(years) | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab | Total |
|---|---|---|---|
| Mean | 65.5 ± 10.48 | 65.6 ± 10.02 | 65.5 ± 10.20 |
| Sex: Female, Male(Participants) | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab | Total |
|---|---|---|---|
| Female | 7 | 4 | 11 |
| Male | 35 | 36 | 71 |
| Race/Ethnicity, Customized(Participants) | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab | Total |
|---|---|---|---|
| ASIAN | 22 | 18 | 40 |
| BLACK OR AFRICAN AMERICAN | 1 | 1 | 2 |
| WHITE | 13 | 18 | 31 |
| NOT COLLECTED OR UNKNOWN | 6 | 3 | 9 |
| Race/Ethnicity, Customized(Participants) | Relatlimab + Nivolumab + Bevacizumab | Placebo + Nivolumab + Bevacizumab | Total |
|---|---|---|---|
| HISPANIC OR LATINO | 5 | 3 | 8 |
| NOT HISPANIC OR LATINO | 34 | 34 | 68 |
| UNKNOWN | 2 | 2 | 4 |
| NOT REPORTED | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2022 to primary completion in Jul 2025, 38 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's 38 months is below that.
Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Relatlimab